StockNews.AI
ALGS
StockNews.AI
162 days

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

1. Aligos reported pivotal business progress and Q4 2024 financial results. 2. Positive advancements for ALG-000184 towards Phase 2 study begin mid-2025. 3. A $105 million private placement boosts funding into 2026 for operations. 4. Strong interim data for ALG-000184 shows 100% HBV DNA suppression. 5. ALG-055009 and ALG-097558 show promising early results for liver and viral diseases.

16m saved
Insight
Article

FAQ

Why Bullish?

The positive clinical results and successful fundraising signal a bright future for ALGS.

How important is it?

Positive clinical trial progress and enhanced funding create long-term investor enthusiasm for ALGS.

Why Long Term?

Ongoing studies and potential market introduction of therapies could drive long-term growth.

Related Companies

GILDNOVNVRTX
March 10, 2025 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “That future looks bright as we move ALG-000184 closer towards a Phase 2 clinical study, which is expected to begin in mid-2025. We continue to believe our CAM-E has the potential to be a first- and best-in-class candidate, by acting as a disease modifying agent for patients in need of better outcomes. Our recent fundraising is backed by investors supportive of our vision for ALG-000184, which has the potential to replace standard of care and become the backbone of treatment for next-generation therapies for chronic hepatitis B virus infection.” Recent Business Progress Corporate Updates Lesley Ann Calhoun was promoted to Executive Vice President, Chief Operating Officer and Chief Financial OfficerThe Company completed a $105 million private placement financing on February 13, 2025, which included participation from both new and existing institutional investors Pipeline Updates ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus infection Dosing continues in the ongoing Phase 1 study, with subjects expected to dose for up to 96 weeks. 96-week data readouts are planned to be presented this year at upcoming scientific conferencesInterim data from up to 92 weeks following an oral daily dose of 300 mg ALG-000184 in both HBeAg+ and HBeAg- subjects with chronic hepatitis B virus infection were presented at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024 Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

Related News